Yüklüyor......
Regulation of temozolomide resistance in glioma cells via the RIP2/NF‐κB/MGMT pathway
BACKGROUND: Temozolomide (TMZ) is a first‐line chemotherapy drug for the treatment of malignant glioma and resistance to it poses a major challenge. Receptor‐interacting protein 2 (RIP2) is associated with the malignant character of cancer cells. However, it remains unclear whether RIP2 is involved...
Kaydedildi:
| Yayımlandı: | CNS Neurosci Ther |
|---|---|
| Asıl Yazarlar: | , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8025621/ https://ncbi.nlm.nih.gov/pubmed/33460245 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cns.13591 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|